KURA ONCOLOGY, INC. Proceeds, Issuance of Shares, Share-based Payment Arrangement, Excluding Option Exercised
KURA ONCOLOGY, INC. (KURA) reported Proceeds, Issuance of Shares, Share-based Payment Arrangement, Excluding Option Exercised of $303.00 thousand for the 3-month period ending 2022-03-31, per its 10-Q filed 2022-05-04.
Discontinued › Cash Flow › Financing Activities
us-gaap:ProceedsFromIssuanceOfSharesUnderIncentiveAndShareBasedCompensationPlans · last filed 2022-05-04
- KURA ONCOLOGY, INC. proceeds, issuance of shares, share-based payment arrangement, excluding option exercised for the quarter ending 2022-03-31 was $303.00K, a 63.45% decline year-over-year.
- KURA ONCOLOGY, INC. proceeds, issuance of shares, share-based payment arrangement, excluding option exercised for the quarter ending 2021-03-31 was $829.00K.
| Period end | Proceeds, Issuance of Shares, Share-based Payment Arrangement, Excluding Option Exercised 3 month |
|---|---|
| 2022-03-31 | $303.00K 10-Q · filed 2022-05-04 |
| 2021-03-31 | $829.00K 10-Q · filed 2022-05-04 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Arbutus Biopharma Corp (ABUS) | $0.965B | 6.19 | |
| Corvus Pharmaceuticals, Inc. (CRVS) | United States | $0.994B | -23.25 |
| Jade Biosciences, Inc. (JBIO) | United States | $0.936B | -9.21 |
| Janux Therapeutics, Inc. (JANX) | United States | $1.019B | -9.15 |
| Pacira BioSciences, Inc. (PCRX) | United States | $1.020B | 69.03 |
| MoonLake Immunotherapeutics (MLTX) | Switzerland | $1.031B | -5.43 |
| Apnimed, Inc. (APMD) | United States | $0.899B | |
| RIGEL PHARMACEUTICALS INC (RIGL) | United States | $0.893B | 2.25 |
| Savara Inc (SVRA) | United States | $1.044B | -9.10 |
| Theravance Biopharma, Inc. (TBPH) | $0.885B | 16.40 |